Piensa En Chronic by Pev Seeds Bank
Indica × Sativa
Piensa En Chronic, developed by PEV Seeds Bank, is a hybrid strain resulting from a careful fusion of indica and sativa genetics. This strain aims to provide both a calming sensation and a mental uplift, making it appealing to a wide range of cannabis users.
Appearance
The buds of Piensa En Chronic are characterized by their density and a rich green coloration, often accented with subtle purple undertones. Close examination reveals deep burgundy pistils against a backdrop of abundant, resin-coated trichomes. The plant's leaves are broad with serrated edges, and the buds are typically adorned with sparkling crystals.
Aroma & Flavor
Piensa En Chronic presents a complex aroma that blends pungent, earthy, and musky notes with an underlying sweetness and spice. Connoisseurs may detect hints of pine and cedar. The flavor profile mirrors the aroma, offering a combination of earthiness, sweet spice, and citrus zest, with a smooth, lingering finish.
Effects
This hybrid strain is known for delivering a balanced experience, combining calming sensations with a cerebral uplift. The effects are generally well-rounded, providing a duality that appeals to both those seeking relaxation and mental stimulation.
Terpenes & Cannabinoids
Piensa En Chronic typically contains THC levels ranging from 18% to 24%, with trace amounts of CBD (<1%). Key terpenes identified include myrcene, caryophyllene, limonene, and pinene, contributing to its distinct aroma, flavor, and potential therapeutic properties. The cannabinoid profile is thought to contribute to its balanced effects.
Growing
Information regarding specific growing details such as difficulty, flowering time, yield, or optimal environment is not detailed in the provided source notes. However, the strain's genetic makeup suggests a robust plant structure.
Origins & Lineage
Developed by PEV Seeds Bank, Piensa En Chronic is the result of meticulous breeding efforts aimed at combining the best attributes of indica and sativa genetics. The strain was first formulated in limited experimental runs in 2015 before its broader market release, noted for its balanced blend of effects.